Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM

Open source

DOI: 10.1038/s41408-024-01030-w
Published: 2024 Apr 22
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-024-01030-w,
  title = {Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.},
  author = {Callander NS and Silbermann R and Kaufman JL and Godby KN and Laubach J and Schmidt TM and Sborov DW and Medvedova E and Reeves B and Dhakal B and Rodriguez C and Chhabra S and Chari A and Bal S and Anderson LD Jr and Dholaria BR and Nathwani N and Hari P and Shah N and Bumma N and Holstein SA and Costello C and Jakubowiak A and Wildes TM and Orlowski RZ and Shain KH and Cowan AJ and Pei H and Cortoos A and Patel S and Lin TS and Giri S and Costa LJ and Usmani SZ and Richardson PG and Voorhees PM},
  year = {2024},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-024-01030-w},
  url = {https://doi.org/10.1038/s41408-024-01030-w}
}

RIS

TY  - JOUR
TI  - Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
AU  - Callander NS
AU  - Silbermann R
AU  - Kaufman JL
AU  - Godby KN
AU  - Laubach J
AU  - Schmidt TM
AU  - Sborov DW
AU  - Medvedova E
AU  - Reeves B
AU  - Dhakal B
AU  - Rodriguez C
AU  - Chhabra S
AU  - Chari A
AU  - Bal S
AU  - Anderson LD Jr
AU  - Dholaria BR
AU  - Nathwani N
AU  - Hari P
AU  - Shah N
AU  - Bumma N
AU  - Holstein SA
AU  - Costello C
AU  - Jakubowiak A
AU  - Wildes TM
AU  - Orlowski RZ
AU  - Shain KH
AU  - Cowan AJ
AU  - Pei H
AU  - Cortoos A
AU  - Patel S
AU  - Lin TS
AU  - Giri S
AU  - Costa LJ
AU  - Usmani SZ
AU  - Richardson PG
AU  - Voorhees PM
PY  - 2024
JO  - Blood cancer journal
DO  - 10.1038/s41408-024-01030-w
UR  - https://doi.org/10.1038/s41408-024-01030-w
ER  -

APA

NS, C., R, S., JL, K., KN, G., J, L., TM, S., DW, S., E, M., B, R., B, D., C, R., S, C., A, C., S, B., Jr, A. L., BR, D., N, N., P, H., N, S., N, B., SA, H., C, C., A, J., TM, W., RZ, O., KH, S., AJ, C., H, P., A, C., S, P., TS, L., S, G., LJ, C., SZ, U., PG, R., & PM, V. (2024). Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.. Blood cancer journal. https://doi.org/10.1038/s41408-024-01030-w

Source records

pubmed · retrieved 2026-09-27T13:10:50.729Z